Bristol Myers Squibb to share major Breyanzi updates at ICML 2025

BMS announced the first disclosure of the primary analysis results of the marginal zone lymphoma (MZL) cohort of TRANSCEND FL, an open-label, global, multicenter, Phase II, single-arm study evaluating Breyanzi (lisocabtagene maraleucel; liso-cel) in patients with relapsed or refractory disease. The new data will be presented at the 2025 International Conference on Malignant Lymphoma (ICML) in an oral presentation on June 19, building on positive topline results announced in February. (some of this data is to be entered on the Breyanzi entry on PE.

Additional key Bristol Myers Squibb data presentations on liso-cel at ICML 2025 include:

Title: Lisocabtagene maraleucel in R/R FL (TRANSCEND FL): impact of prior lines of therapy, bendamustine exposure, and disease progression ≤24 months of initial systemic therapy
Oral presentation: Thursday, June 19
Key findings: Results support the sustained clinical benefit and safety profile of liso-cel for patients with R/R regardless of POD24 status and prior bendamustine exposure with a trend for better outcomes in earlier lines of therapy.

Title: Matching-adjusted indirect comparison of lisocabtagene maraleucel versus epcoritamab in patients with third-line or later relapsed or refractory follicular lymphoma
Poster session: Thursday, June 19
Key findings: The data support liso-cel as an effective treatment for patients with third-line plus R/R FL, potentially offering improved efficacy over epcoritamab in this setting.

Title: Comparative outcomes of lisocabtagene maraleucel (liso-cel) versus an external control arm (ECA) in third-line or later (3L+) R/R follicular lymphoma (FL)
Poster session: Friday, June 20
Key findings: Liso-cel appeared to show better efficacy than SOC therapies in patients with third-line plus R/R FL, further supporting it as an important treatment option to improve patient outcomes in this setting.

Title: Optimizing post–chimeric antigen receptor T cell monitoring: evidence across lisocabtagene maraleucel pivotal clinical trials and real-world experience (recently presented at the American Society of Clinical Oncology meeting)
Poster session: Friday, June 20
Key findings: Results showed that most cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome events in patients treated with liso-cel occurred less than 2 weeks after infusion and were not severe, providing insight into the onset of these events across clinical trials and in the real-world setting.